Role of serum IL-17A level in patients with polycystic ovary syndrome

doi:10.3969/j.issn.1673-8640.2018.07.005

Abstract

Abstract:

Objective To investigate the role of serum interleukin（IL）-17A level in patients with polycystic ovary syndrome （PCOS）. Methods A total of 45 PCOS patients were enrolled,45 healthy women were enrolled as healthy control group,and 38 non-PCOS patients were enrolled as disease control group. Serum levels of dehydroepiandrosterone sulphate （DHEAS） and total testosterone （TT） were determined. The levels of serum IL-17A, IL-6 and transforming growth factor beta₁（TGF-β₁） were determined by enzyme-linked immunosorbent assay （ELISA）. Results Serum TT, DHEAS,IL-17A,IL-6 and TGF-β₁ levels were higher in PCOS group than those in healthy and disease control groups （P<0.05）. Serum level of TT was positively related to IL-17A,IL-6 and TGF-β₁（r=0.632,P<0.01;r=0.650,P<0.05;r=0.708,P<0.05）. After treatment,serum levels of IL-17A,IL-6 and TGF-β₁ in PCOS group were lower than those before treatment. Conclusions PCOS patients have increased serum IL-17A level,and serum IL-17A could be a biomarker for PCOS.

Key words: Interleukin 17A, Polycystic ovary syndrome, Clinical significance

CLC Number:

R446.62

WANG Jing, CHEN Li, LIU Chunhua, LI Lichun. Role of serum IL-17A level in patients with polycystic ovary syndrome[J]. Laboratory Medicine, 2018, 33(7): 601-603.

Figures/Tables 2

References 16

[1]	LUQUE-RAMÍREZ M, ESCOBAR-MORREALE H F. Polycystic ovary syndrome as a paradigm for prehypertension, prediabetes, and preobesity[J]. Curr Hypertens Rep, 2014, 16(12):500.
[2]	DI PIETRO M, PARBORELL F, IRUSTA G, et al.Metformin regulates ovarian angiogenesis and follicular development in a female polycystic ovary syndrome rat model[J]. Endocrinology, 2015, 156(4): 1453-1463.
[3]	PALOMBA S, LA SALA G B. Pregnancy complications in women with polycystic ovary syndrome: importance of diagnostic criteria or of phenotypic features?[J]. Hum Reprod, 2016, 31(1): 223-224.
[4]	LEGRO R S, BRZYSKI R G, DIAMOND M P, et al.Letrozole versus clomiphene for infertility in the polycystic ovary syndrome[J]. N Engl J Med, 2014, 371(2): 119-129.
[5]	华飞. 多囊卵巢综合征患者合并胰岛素抵抗、代谢综合征及抑郁症的研究与评估[D]. 苏州:苏州大学,2016.
[6]	赵玲玲. 多囊卵巢综合征患者代谢特征与胰岛素抵抗的相关性分析[D]. 长春:吉林大学,2015.
[7]	AMATO M C, VESCO R, VIGNERI E, et al.Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance[J]. J Endocrinol Invest, 2015, 38(12): 1319-1326.
[8]	YILMAZ H, CELIK H T, OZDEMIR O, et al.Serum galectin-3 levels in women with PCOS[J]. J Endocrinol Invest, 2014, 37(2):181-187.
[9]	王立娜, 郑丽娜, 芦珊珊. 吡格列酮对多囊卵巢综合征患者血清CRP、IL-6、TNF-α水平的影响[J]. 山东医药,2015,55(38):58-59.
[10]	陈沛林,陈光元,谢家滨,等. 血清炎症因子在多囊卵巢综合征患者中的表达及其临床意义[J]. 海南医学,2016,27(12):1945-1947.
[11]	李丹, 李玉洁, 杨庆,等. 血管内皮功能障碍与动脉粥样硬化研究进展[J]. 中国实验方剂学杂志, 2012, 18(8):272-276.
[12]	车业娜. 雄激素导致PCOS发病机理的研究[D]. 南京:南京大学,2012.
[13]	LONG X, LI R, YANG Y, et al.Overexpression of IL-18 in the proliferative phase endometrium of patients with polycystic ovary syndrome[J]. Reprod Sci, 2017, 24(2): 252-257.
[14]	COVINGTON J D, TAM C S, PASARICA M, et al.Higher circulating leukocytes in women with PCOS is reversed by aerobic exercise[J]. Biochimie, 2014, 124: 27-33.
[15]	SPRITZER P M, LECKE S B, SATLER F, et al.Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome[J]. Reproduction, 2015, 149(5): R219-R227.
[16]	SHERLOCK J P, TAYLOR P C, BUCKLEY C D.The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases[J]. Curr Opin Rheumatol, 2015, 27(1):71-75.

组别	例数	DHEAS（μmol/L）	TT（nmol/L）	IL-17A（pg/mL）	IL-6（pg/mL）	TGF-β₁（ng/mL）
PCOS组	45	15.5±7.8^*#	3.7±1.2^**##	18.6（10.1~42.4）	14.6±5.7^**##	45.3±10.6^**##
疾病对照组	38	11.4±5.8	1.7±0.6	6.9（4.4~14.6）	9.4±4.3	33.4±9.8
正常对照组	45	10.9±5.5	1.6±0.5	5.1（3.2~13.9）	8.1±3.2	32.1±9.0

组别	例数	DHEAS（μmol/L）	TT（nmol/L）	IL-17A（pg/mL）	IL-6（pg/mL）	TGF-β₁（ng/mL）
PCOS组	45	15.5±7.8^*#	3.7±1.2^**##	18.6（10.1~42.4）	14.6±5.7^**##	45.3±10.6^**##
疾病对照组	38	11.4±5.8	1.7±0.6	6.9（4.4~14.6）	9.4±4.3	33.4±9.8
正常对照组	45	10.9±5.5	1.6±0.5	5.1（3.2~13.9）	8.1±3.2	32.1±9.0

组别	例数	IL-17A （pg/mL）	IL-6 （pg/mL）	TGF-β₁ （ng/mL）
治疗前	45	18.6（10.1~42.4）	14.6±5.7	45.3±10.6
治疗后	45	6.0（3.9~16.7）^*	11.8±4.9^*	39.9±11.3^*

组别	例数	IL-17A （pg/mL）	IL-6 （pg/mL）	TGF-β₁ （ng/mL）
治疗前	45	18.6（10.1~42.4）	14.6±5.7	45.3±10.6
治疗后	45	6.0（3.9~16.7）^*	11.8±4.9^*	39.9±11.3^*